176 related articles for article (PubMed ID: 31789374)
1. Comparison between IMP carbapenemase-producing Enterobacteriaceae and non-carbapenemase-producing Enterobacteriaceae: a multicentre prospective study of the clinical and molecular epidemiology of carbapenem-resistant Enterobacteriaceae.
Hayakawa K; Nakano R; Hase R; Shimatani M; Kato H; Hasumi J; Doi A; Sekiya N; Nei T; Okinaka K; Kasahara K; Kurai H; Nagashima M; Miyoshi-Akiyama T; Kakuta R; Yano H; Ohmagari N
J Antimicrob Chemother; 2020 Mar; 75(3):697-708. PubMed ID: 31789374
[TBL] [Abstract][Full Text] [Related]
2. A Matched Case-Case-Control Study of the Impact of Clinical Outcomes and Risk Factors of Patients with IMP-Type Carbapenemase-Producing Carbapenem-Resistant
Saito S; Hayakawa K; Tsuzuki S; Ishikane M; Nagashima M; Mezaki K; Sugiki Y; Tajima T; Matsunaga N; Ide S; Kinoshita N; Kusama Y; Fujitomo Y; Nakamoto T; Toda Y; Kaku M; Kodama EN; Ohmagari N
Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33257451
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for acquisition of carbapenemase-producing versus non-carbapenemase-producing enterobacterales: a case-control study.
Hassoun-Kheir N; Hussein K; Karram M; Saffuri M; Badaan S; Peleg S; de Kraker MEA; Aboelhega W; Warman S; Alon T; Eluk O; Geffen Y; Paul M
Clin Microbiol Infect; 2023 May; 29(5):629-634. PubMed ID: 36641053
[TBL] [Abstract][Full Text] [Related]
4. Trends and molecular characteristics of carbapenemase-producing Enterobacteriaceae in Japanese hospital from 2006 to 2015.
Eda R; Nakamura M; Takayama Y; Maehana S; Nakano R; Yano H; Kitasato H
J Infect Chemother; 2020 Jul; 26(7):667-671. PubMed ID: 32222331
[TBL] [Abstract][Full Text] [Related]
5. Antecedent Carbapenem Exposure as a Risk Factor for Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae and Carbapenemase-Producing Enterobacteriaceae.
Marimuthu K; Ng OT; Cherng BPZ; Fong RKC; Pada SK; De PP; Ooi ST; Smitasin N; Thoon KC; Krishnan PU; Ang MLT; Chan DSG; Kwa ALH; Deepak RN; Chan YK; Chan YFZ; Huan X; Zaw Linn K; Tee NWS; Tan TY; Koh TH; Lin RTP; Hsu LY; Sengupta S; Paterson DL; Perencevich E; Harbarth S; Teo J; Venkatachalam I;
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31383670
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and Characteristics of Carbapenemase-Producing Enterobacteriaceae in Three Tertiary-Care Korean University Hospitals between 2017 and 2018.
Kim SH; Kim GR; Jeong J; Kim S; Shin JH
Jpn J Infect Dis; 2020 Nov; 73(6):431-436. PubMed ID: 32475870
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study.
Nicolas-Chanoine MH; Vigan M; Laouénan C; Robert J;
Eur J Clin Microbiol Infect Dis; 2019 Feb; 38(2):383-393. PubMed ID: 30488368
[TBL] [Abstract][Full Text] [Related]
8. Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla
Solgi H; Badmasti F; Aminzadeh Z; Giske CG; Pourahmad M; Vaziri F; Havaei SA; Shahcheraghi F
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2127-2135. PubMed ID: 28639165
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model.
Hagihara M; Kato H; Sugano T; Okade H; Sato N; Shibata Y; Sakanashi D; Asai N; Koizumi Y; Suematsu H; Yamagishi Y; Mikamo H
Int J Antimicrob Agents; 2021 May; 57(5):106330. PubMed ID: 33789129
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of multidrug-resistant Enterobacteriaceae in Sri Lanka: First evidence of bla
Kumudunie WGM; Wijesooriya LI; Namalie KD; Sunil-Chandra NP; Wijayasinghe YS
J Infect Public Health; 2020 Sep; 13(9):1330-1335. PubMed ID: 32439355
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Genomic Characterization of Carbapenemase-producing Enterobacteriaceae (CPE) Reveals Changing Pattern of CPE Isolated in Hong Kong Hospitals.
Zhu C; Li C; Lai CKC; Ng R; Chau KY; Wong KT; Lo NWS; Barua N; Yang Y; Liyanapathirana V; Hui M; Lai RW; Fung KSC; Tsang DN; Ip M
Int J Antimicrob Agents; 2021 Nov; 58(5):106430. PubMed ID: 34525401
[TBL] [Abstract][Full Text] [Related]
12. Molecular characteristics of carbapenemase-producing Enterobacterales in the Netherlands; results of the 2014-2018 national laboratory surveillance.
van der Zwaluw K; Witteveen S; Wielders L; van Santen M; Landman F; de Haan A; Schouls LM; Bosch T;
Clin Microbiol Infect; 2020 Oct; 26(10):1412.e7-1412.e12. PubMed ID: 32006688
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of carbapenem resistance and carbapenemase production among Enterobacteriaceae isolated from urine in the UK: results of the UK infection-Carbapenem Resistance Evaluation Surveillance Trial (iCREST-UK).
Woodford N; Xu-McCrae L; Mushtaq S; Wu HHT; Ellington MJ; Lancaster O; Davies F; Donaldson H; Rao GG; Verma A; Wareham DW; Ciesielczuk H; Stone GG; Irani PM; Bracher S; Hawkey PM
J Antimicrob Chemother; 2018 Mar; 73(3):698-702. PubMed ID: 29253163
[TBL] [Abstract][Full Text] [Related]
14. Activity of ceftazidime-avibactam against carbapenemase-producing Enterobacteriaceae from urine specimens obtained during the infection-carbapenem resistance evaluation surveillance trial (iCREST) in Spain.
García-Castillo M; García-Fernández S; Gómez-Gil R; Pitart C; Oviaño M; Gracia-Ahufinger I; Díaz-Regañón J; Tato M; Cantón R;
Int J Antimicrob Agents; 2018 Mar; 51(3):511-515. PubMed ID: 29371104
[TBL] [Abstract][Full Text] [Related]
15. Genomic and clinical characterisation of multidrug-resistant carbapenemase-producing ST231 and ST16 Klebsiella pneumoniae isolates colonising patients at Siriraj hospital, Bangkok, Thailand from 2015 to 2017.
Boonyasiri A; Jauneikaite E; Brinkac LM; Greco C; Lerdlamyong K; Tangkoskul T; Nguyen K; Thamlikitkul V; Fouts DE
BMC Infect Dis; 2021 Feb; 21(1):142. PubMed ID: 33541274
[TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics and treatment of IMP-type carbapenemase-producing Enterobacteriaceae bacteremia: Case series and literature review.
Soneda K; Uda K; Araki K; Murakoshi T; Yuza Y; Saito O; Kinoshita K; Higuchi H; Horikoshi Y
J Infect Chemother; 2023 Jan; 29(1):26-32. PubMed ID: 36100144
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and risk factors of rectal colonization of carbapenemase-producing Enterobacteriaceae among high-risk patients from ICU and HSCT wards in a university hospital.
Yan L; Sun J; Xu X; Huang S
Antimicrob Resist Infect Control; 2020 Sep; 9(1):155. PubMed ID: 32967718
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology and Transmission of Carbapenemase-Producing
Aung AH; Kanagasabai K; Koh J; Hon PY; Ang B; Lye D; Chen SL; Chow A
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0258420. PubMed ID: 34001509
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of meropenem/vaborbactam and characterisation of carbapenem resistance mechanisms among carbapenem-resistant Enterobacteriaceae from the 2015 meropenem/vaborbactam surveillance programme.
Pfaller MA; Huband MD; Mendes RE; Flamm RK; Castanheira M
Int J Antimicrob Agents; 2018 Aug; 52(2):144-150. PubMed ID: 29510189
[TBL] [Abstract][Full Text] [Related]
20. Molecular and Epidemiological Characteristics of Carbapenemase-Producing Klebsiella pneumoniae Clinical Isolates in Japan.
Yonekawa S; Mizuno T; Nakano R; Nakano A; Suzuki Y; Asada T; Ishii A; Kakuta N; Tsubaki K; Mizuno S; Ogawa M; Yano H; Kasahara K; Mikasa K
mSphere; 2020 Oct; 5(5):. PubMed ID: 33087515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
